AlloVir(US:ALVR)2025-05-14 12:09Financial Performance - As of March 31, 2025, Kalaris had cash and cash equivalents of $101.0 million, a significant increase from $1.6 million as of December 31, 2024, primarily due to the merger with AlloVir[5] - The net loss for Q1 2025 was $10.2 million, or $2.52 per share, compared to a net loss of $3.4 million, or $2.60 per share, in Q1 2024[8] - Total operating expenses for Q1 2025 were $10.4 million, significantly higher than $2.6 million in Q1 2024[15] - General and administrative expenses rose to $4.3 million in Q1 2025 from $0.6 million in Q1 2024, driven by a one-time charge for AlloVir's insurance and increased professional fees[7] - Research and development expenses for Q1 2025 were $6.0 million, up from $2.0 million in Q1 2024, reflecting increased costs related to manufacturing and clinical trials[6] Operational Developments - The merger with AlloVir was completed in March 2025, expanding Kalaris' operational capabilities[4] - Kalaris is currently enrolling patients in a Phase 1 trial for TH103, with initial clinical data expected in Q4 2025[4] - Kalaris plans to develop TH103 for additional retinal diseases beyond neovascular Age-related Macular Degeneration (nAMD)[9] Shareholder Information - The total number of shares outstanding as of March 31, 2025, was 18,702,418[8] - Kalaris' total assets as of March 31, 2025, were $103.1 million, compared to $6.2 million as of December 31, 2024[17]